You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
A long-acting antiretroviral drug given as an injection every 2 months powerfully protected uninfected people from HIV in a large-scale clinical trial. Although it was cut short by the COVID-19 pandemic and has not been published in a peer-reviewed journal or presented at a meeting, the study holds out hope of preventing HIV infections in high-risk groups without the need to take pills every day, which many people find difficult. The trial, sponsored by the U.S. National Institute of Allergy and Infectious Diseases, compared the experimental drug cabotegravir with Truvada, a daily pill combining two antiretroviral compounds that is the standard regimen for pre-exposure prophylaxis. The overall result indicates cabotegravir works just as well as Truvada, and perhaps even better.
